Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With ... - UroToday
Darolutamide plus androgen-deprivation therapy (ADT) significantly improved radiological progression-free survival (rPFS) by 46% versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), with consistent benefits across subgroups and a favorable safety profile.
Related Clinical Trials
Reference News
Darolutamide plus ADT significantly improves rPFS in mHSPC compared to ADT plus placebo, delaying castration-resistant disease and pain progression, according to the ARANOTE trial presented at ESMO 2024. Darolutamide's favorable safety profile supports its potential as a new standard of care for mHSPC without docetaxel.
Darolutamide plus androgen-deprivation therapy (ADT) significantly improved radiological progression-free survival (rPFS) by 46% versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), with consistent benefits across subgroups and a favorable safety profile.
Darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% in patients with metastatic hormone-sensitive prostate cancer (mHSPC), with consistent benefits across subgroups. Treatment emergent adverse events were low and similar between groups. The ARANOTE trial results were presented at the 2024 ESMO Congress and published in The Journal of Clinical Oncology, supporting the potential of darolutamide as a foundational therapy in prostate cancer.
The ARANOTE trial investigates darolutamide plus ADT versus placebo plus ADT in metastatic hormone-sensitive prostate cancer, showing significant improvements in radiographic progression-free survival, time to mCRPC, pain progression, and PSA responses. The study includes a diverse patient population and highlights darolutamide's favorable safety profile, with adverse events similar to placebo. The potential for darolutamide to become a new standard of care is discussed.